MOULINATH BANERJEE

Moulinath Banerjee is a Senior Clinical Lecturer & Consultant affiliated with the Medical School. His research focuses on diabetes complications, particularly diabetic ketoacidosis (DKA) and its interplay with conditions like COVID-19. He investigates pharmacological interventions such as SGLT2 inhibitors and PCSK9 monoclonal antibodies, emphasizing real-world clinical applications. His work bridges endocrinology, critical care, and public health, contributing to improved management strategies for metabolic disorders. Key studies include analyzing DKA outcomes in hospitalized patients and exploring misclassification in Type 1 diabetes through islet antibody testing.

Research interests span clinical pharmacology, metabolic pathways in diabetes, and cardiovascular risk mitigation. Notable collaborations include the ABCD Covid-19 national audit and multicenter trials evaluating PCSK9 inhibitors. His findings have informed guidelines on DKA treatment and highlighted emerging therapies' safety profiles during pandemics.